Rigel Pharmaceuticals マネジメント

マネジメント基準チェック /34

Rigel Pharmaceuticalsの CEO はRaul Rodriguezで、 May2010年に任命され、の在任期間は 14.5年です。の年間総報酬は$ 3.44Mで、 21.2%給与と78.8%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.74%を直接所有しており、その価値は$ 3.42M 。経営陣と取締役会の平均在任期間はそれぞれ3.5年と6.3年です。

主要情報

Raul Rodriguez

最高経営責任者

US$3.4m

報酬総額

CEO給与比率	21.2%
CEO在任期間	14.5yrs
CEOの所有権	0.7%
経営陣の平均在職期間	3.5yrs
取締役会の平均在任期間	6.3yrs

経営陣の近況

Recent updates

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Could Be 36% Below Their Intrinsic Value Estimate

Nov 08

Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships

Oct 10

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Fly 31% But Investors Aren't Buying For Growth

Sep 25

There's No Escaping Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Muted Revenues Despite A 29% Share Price Rise

Jul 30

Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential

Jul 24

Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding

May 01

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 08

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement

Mar 04

Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report

Feb 23

Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S

Jan 15

CEO報酬分析

Rigel Pharmaceuticals の収益と比較して、Raul Rodriguez の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	US$4m
Jun 30 2024	n/a	n/a	-US$14m
Mar 31 2024	n/a	n/a	-US$20m
Dec 31 2023	US$3m	US$728k	-US$25m
Sep 30 2023	n/a	n/a	-US$24m
Jun 30 2023	n/a	n/a	-US$38m
Mar 31 2023	n/a	n/a	-US$45m
Dec 31 2022	US$3m	US$700k	-US$59m
Sep 30 2022	n/a	n/a	-US$83m
Jun 30 2022	n/a	n/a	-US$85m
Mar 31 2022	n/a	n/a	-US$85m
Dec 31 2021	US$3m	US$662k	-US$18m
Sep 30 2021	n/a	n/a	-US$15m
Jun 30 2021	n/a	n/a	-US$8m
Mar 31 2021	n/a	n/a	-US$11m
Dec 31 2020	US$3m	US$662k	-US$30m
Sep 30 2020	n/a	n/a	-US$28m
Jun 30 2020	n/a	n/a	-US$25m
Mar 31 2020	n/a	n/a	-US$28m
Dec 31 2019	US$3m	US$649k	-US$67m
Sep 30 2019	n/a	n/a	-US$46m
Jun 30 2019	n/a	n/a	-US$59m
Mar 31 2019	n/a	n/a	-US$64m
Dec 31 2018	US$4m	US$637k	-US$70m
Sep 30 2018	n/a	n/a	-US$100m
Jun 30 2018	n/a	n/a	-US$93m
Mar 31 2018	n/a	n/a	-US$87m
Dec 31 2017	US$2m	US$618k	-US$78m

報酬と市場: Raulの総報酬 ($USD 3.44M ) は、 US市場 ($USD 2.14M ) の同規模の企業の平均を上回っています。

報酬と収益: Raulの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Raul Rodriguez (63 yo)

14.5yrs

在職期間

US$3,440,790

報酬

Mr. Raul R. Rodriguez has been the Chief Executive Officer and Director of Rigel Pharmaceuticals, Inc., since November 2014 and its President since May 2010. Mr. Rodriguez served as Chief Operating Officer...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Raul Rodriguez	President	14.5yrs	US$3.44m	0.74% $ 3.4m
Dean Schorno	Executive VP & CFO	6.5yrs	US$1.21m	0.069% $ 316.7k
Raymond Furey	Executive VP	1.9yrs	US$683.00k	0.0028% $ 13.0k
David Santos	Executive VP & Chief Commercial Officer	4.3yrs	US$1.34m	0.031% $ 143.4k
Julie Patel	Senior VP of Human Resources	2.8yrs	データなし	データなし
Esteban Masuda	Executive Vice President of Research	8.2yrs	US$796.09k	データなし
Joseph Lasaga	Executive VP & Chief Business Officer	less than a year	データなし	データなし
Lisa Rojkjaer	Executive VP & Chief Medical Officer	less than a year	データなし	データなし
Tarek Sallam	Vice President of Marketing	no data	データなし	データなし

3.5yrs

平均在職期間

61yo

平均年齢

経験豊富な経営陣: RIGLの経営陣は経験豊富であると考えられます ( 3.5年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Raul Rodriguez	President	10yrs	US$3.44m	0.74% $ 3.4m
Walter Moos	Independent Director	27.7yrs	US$138.58k	0.044% $ 201.1k
Jane Wasman	Independent Director	5.7yrs	US$145.58k	0.043% $ 195.3k
Gregory Lapointe	Independent Chairman of the Board	7yrs	US$190.58k	0.043% $ 195.3k
Kamil Jackson	Independent Director	2.9yrs	US$140.58k	0.025% $ 113.9k
Alison Hannah	Independent Director	3.5yrs	US$212.98k	0.032% $ 146.5k

6.3yrs

平均在職期間

65yo

平均年齢

経験豊富なボード: RIGLの取締役会は経験豊富であると考えられます ( 6.3年の平均在任期間)。

Rigel Pharmaceuticals マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Insufficient new directors

Rigel Pharmaceuticals, Inc., Annual General Meeting, May 22, 2024

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer as Chief Medical Officer

President recently sold US$60k worth of stock

Rigel Pharmaceuticals, Inc. Announces Resignation of Wolfgang Dummer as Executive Vice President and Chief Medical Officer, Effective March 31, 2023

President recently bought US$688k worth of stock

Recent updates

Price target increased by 7.2% to US$28.67

Now 68% overvalued after recent price rise

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Could Be 36% Below Their Intrinsic Value Estimate

Rigel Pharmaceuticals, Inc. Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition

Rigel Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Fly 31% But Investors Aren't Buying For Growth

Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML

Price target increased by 34% to US$26.75

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Forecast breakeven date moved forward to 2024

There's No Escaping Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Muted Revenues Despite A 29% Share Price Rise

Rigel Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Consensus EPS estimates upgraded to US$0.43 loss

Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential

Price target increased by 44% to US$65.33

Consensus EPS estimates upgraded to US$0.65 loss

Rigel Pharmaceuticals Completes Transfer of GAVRETO®? (pralsetinib) New Drug Application

Rigel Pharmaceuticals, Inc. Announces Five Presentations at the EHA2024 Hybrid Congress

Insufficient new directors

Consensus EPS estimates upgraded to US$0.062 loss

Consensus EPS estimates upgraded to US$0.073 loss

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding

Rigel Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Price target increased by 14% to US$5.08

Rigel Pharmaceuticals, Inc., Annual General Meeting, May 22, 2024

Consensus EPS estimates fall by 13%

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer as Chief Medical Officer

Consensus estimates of losses per share improve by 12%

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Forecast breakeven date moved forward to 2025

Price target increased by 10% to US$4.46

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement

Rigel Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report

President recently sold US$60k worth of stock

Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S

No longer forecast to breakeven

New minor risk - Share price stability

Forecast to breakeven in 2025

Rigel Pharmaceuticals, Inc. Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Consensus EPS estimates upgraded to US$0.19 loss

Forecast to breakeven in 2025

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rigel Pharmaceuticals, Inc. Announces Poster Presentations At the 65Th American Society of Hematology Annual Meeting and Exposition

Rigel Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Rigel Pharmaceuticals, Inc. Announces Presentation of Data from the Focus Phase 3 Clinical Trial of Fostamatinib in Hospitalized COVID-19 Patients and Provides Update on ACTIV-4 Host Tissue Trial

Consensus EPS estimates upgraded to US$0.25 loss

New minor risk - Profitability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rigel Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Rigel Pharmaceuticals, Inc. Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML

Rigel Pharmaceuticals, Inc. Announces Second -2-2-Appointment of Olutasidenib as Therapeutics

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2025

Price target increased by 7.6% to US$3.85

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Rigel Pharmaceuticals, Inc. Announces Resignation of Wolfgang Dummer as Executive Vice President and Chief Medical Officer, Effective March 31, 2023

Rigel Pharmaceuticals, Inc. Announces Publication of REZLIDHIA (Olutasidenib) Phase 2 Clinical Results in Blood Advances

National Comprehensive Cancer Network Adds Newly Approved Rigel Pharmaceuticals, Inc.'s REZLIDHIA™ (Olutasidenib) to Clinical Practice Guidelines in Oncology for Acute Myeloid Leukemia

Price target increased to US$4.11

Rigel Pharmaceuticals, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Rigel Pharmaceuticals, Inc. Announces Availability of REZLIDHIA™ (olutasidenib) in the U.S. for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

Rigel Pharmaceuticals, Inc. Doses First Patient in Phase 1b Study of R289 for the Treatment of Lower-Risk Myelodysplastic Syndromes

Rigel Pharmaceuticals, Inc. Announces U.S. FDA Approval of REZLIDHIA™ (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

Rigel Pharmaceuticals Received a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Rigel Pharmaceuticals, Inc. Announces Publication of Early Clinical Data of Olutasidenib in the Lancet Haematology

Third quarter 2022 earnings: EPS exceeds analyst expectations

マネジメント基準チェック /34